{"prompt": "['>grade 3. No serious cardiovascular events within 12 months', 'including, but not limited to, transient ischemic attack (TIA),', 'cerebrovascular accident (CVA), or myocardial infarction (MI).', 'Patients with a history of hypertension must be well-controlled (<', '160/90) on anti-hypertensive therapy.', 'Halabi Nomogram score <195\u00b9 (Risk Category rated as low', 'or', 'intermediate risk)', 'Age >18 years', 'Required Baseline Laboratory Values: ANC 1500/uL; Platelet', 'count 100,000/uL; Creatinine 1.5 X upper limits of normal;', 'Bilirubin 1.5 X upper limits of normal; AST 1.5 X upper limits of', 'normal; Serum testosterone 50 ng/dL', 'ECOG performance status 0-1', 'Medical clearance by treating physician to undergo a symptom-', 'limited cardiopulmonary exercise test and vigorous aerobic and', 'resistance exercise training, and able to complete an acceptable', 'cardiopulmonary exercise test.', 'Exercise Coordination Centre (ECC) review and approval of', \"subject's screening bone scan / areas with bone metastases.\", 'Men participating in vigorous aerobic exercise for >60 min/week or', 'structured resistance exercise >2 days/week, are not eligible.', 'Subject is willing and able to use technological aspects of the trial.', 'The subject is fluent in the language as designated by the institution', 'at which he would be enrolled.', 'Safety Assessments', 'Symptom-limited cardiopulmonary exercise test with ECG during the', 'screening period. Physician clearance* to continue obtained every 6', 'cycles (1 cycle=28 days), vital signs every 6 cycles, ECOG performance', 'status every 3 cycles, concomitant medications each cycle, and AEs', 'assessed each cycle and reported continuously from informed consent', 'until 28 days after cycle 24.', '*For any patient under that management of a cardiologist, additional', 'clearance by his cardiologist is necessary at Cycles 0, 6, and 12.', 'Data Monitoring', 'A central Data Monitoring Committee will be established to oversee the', 'Committee', 'safety of all subjects enrolled in this study. The committee will receive', 'notification every 3 months of the interim and total accrual and significant', 'adverse events. On the discretion of the chair of the DMC, interim analyses', 'may be scheduled as modifications to the protocol. Additional meetings', 'during the study period may occur at the discretion of the Steering', 'Committee. This committee will pass all recommendations to the Research', 'Advisory Committee, who will make the final decisions about study', 'closure, expanding eligibility criteria, etc.', 'Efficacy', 'Overall survival status and cause of death will be ascertained via review', 'Assessments', 'of medical and death records.', 'Primary Endpoint', 'Overall survival', 'Secondary Endpoints', 'Progression-free survival, symptomatic skeletal-related events, pain,', 'opiate use, cancer-related fatigue, metabolic biomarkers, physical', 'function, quality-of-life (QOL) and QOL-adjusted survival', 'INTERVAL Protocol Version 4.0, 19 April 2018', '4']['Other Evaluations', 'Brief Pain Inventory Short Form (BPI-SF), World Health Organization', '(WHO) analgesic scale, Functional Assessment of Cancer Therapy-', 'Prostate (FACT-G), Functional Assessment of Chronic Illness Therapy-', 'Fatigue (FACIT-Fatigue Subscale), EuroQOL five dimension questionnaire', '(EQ-5D-5L), Godin Leisure Time Physical Activity Questionnaire, country-', 'specific food frequency questionnaire, Pittsburgh Sleep Quality Index', '(PSQI); falls; memory; exercise motivation; health economics', 'This is a 1:1 randomised controlled trial in men with metastatic castrate-', 'Rationale for Number', 'of Patients', 'resistant prostate cancer (MCRPC). Eligible, consented participants will be', 'randomised with equal probability to one of two intervention regimens:', 'supervised exercise (SE) group for 48 weeks (12 X 28-day cycles) which', 'tapers progressively to self-management with psychosocial support or', 'psychosocial support for men in the self-directed exercise (SDE) group.', 'Men will be stratified by treatment status at the time of randomization and', 'site.', 'Considering a total enrolment period of 60 months and minimum 36', 'months follow-up for each patient after enrolment; assuming survival time', 'follows an exponential distribution; and assuming a median OS survival of', '33.5 months in the control arm, the sample size required to detect a', 'hazard ratio (HR) of 0.78 with 80% power at significance level of 0.05 is', '824 translating to 412 men in each arm. Accounting for 5% of patients with', 'unknown survival status at 3 years, we aim to enrol 866 men.', 'With 80% power, we will observe median survival times (>216 events in', 'both arms) at 66 months (5.5 years) after the first enrolment.', 'Statistical Analysis', 'An intent-to-treat approach will be used to analyse OS. Patients without', 'Plan for Primary', 'death at the end of follow-up will be censored on the date of the last', 'Endpoint', 'contact (or, if no contact after baseline, at the date of randomisation +', '1', 'day). Kaplan-Meier methods will be used to estimate the median OS for', 'each treatment arm as well as the 1-year, 2-year, and 3-year OS rates', 'and corresponding 95% confidence intervals. A two-sided log-rank test', 'stratified by treatment status at the time of registration (Y/N) and study', 'site will be used to assess the effect of the intervention. Un-stratified log-', 'rank tests will be examined as sensitivity analyses. Cox proportional-', 'hazard regression models will be used to estimate the hazard ratio and', 'its 95% confidence interval to quantify the effect of the intervention on', 'OS, adjusting for stratification factors and other potential confounding', 'factors.', 'Duration of Patient', 'All patients will be followed for OS a minimum of 36 months (for those', 'Participation and', 'men enrolled last during the 3 year enrolment period) after', 'Duration of Study', 'randomisation to observe median survival time in both groups. After the', 'intervention period, participants will complete a set of surveys on a', 'yearly basis; we will contact them, then next of kin and alternate contact,', 'if needed, if we do not hear from them.', 'INTERVAL Protocol Version 4.0, 19 April 2018', '5']\n\n###\n\n", "completion": "END"}